**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 88828

**Manuscript Type:** ORIGINAL ARTICLE

***Clinical and Translational Research***

**Expression of cyclin-dependent kinase 9 is positively correlated with the autophagy level in colon cancer**

Zheng L *et al.* Autophagy in colon cancer

Lei Zheng, Jia Lu, Da-Lu Kong

**Lei Zheng, Da-Lu Kong,** Department of Colorectal Cancer Surgery, National Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy of Tianjin, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China

**Jia Lu,** Department of Infection Management, National Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy of Tianjin, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China

**Co-first authors:** Lei Zheng and Jia Lu.

**Author contributions:** Kong DL conceived and designed the study; Zheng L provided study materials and collected and assembled data; Lu J analyzed data and prepared figures; Zheng L and Lu J wrote the manuscript and contributed equally to the study and as such are co-first authors; All authors read and approved the final manuscript.

**Supported by** the Science and Technology Development Fund of Tianjin Education Commission for Higher Education, No. 2020KJ133; and Tianjin Key Medical Discipline (Specialty) Construction Project, No. TJYXZDXK-009A.

**Corresponding author: Da-Lu Kong, PhD, Doctor,** Department of Colorectal Cancer Surgery, National Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy of Tianjin, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, No. 1 Huanhuxi Road Hexi District, Tianjin 300060, China. kongdalu\_1@163.com

**Received:** October 11, 2023

**Revised:** December 12, 2023

**Accepted:** January 5, 2024

**Published online:** February 15, 2024

**Abstract**

BACKGROUND

Cyclin-dependent kinase 9 (CDK9) expression and autophagy in colorectal cancer (CRC) tissues has not been widely studied. CDK9, a key regulator of transcription, may influence the occurrence and progression of CRC. The expression of autophagy-related genes *BECN1* and drug resistance factor *ABCG2* may also play a role in CRC. Under normal physiological conditions, autophagy can inhibit tumorigenesis, but once a tumor forms, autophagy may promote tumor growth. Therefore, understanding the relationship between autophagy and cancer, particularly how autophagy promotes tumor growth after its formation, is a key motivation for this research.

AIM

To investigate the relationship between CDK9 expression and autophagy in CRC, assess differences in autophagy between left and right colon cancer, and analyze the associations of autophagy-related genes with clinical features and prognosis.

METHODS

We collected tumor tissues and paracarcinoma tissues from colon cancer patients with liver metastasis to observe the level of autophagy in tissues with high levels of CDK9 and low levels of CDK9. We also collected primary tissue from left and right colon cancer patients with liver metastasis to compare the autophagy levels and the expression of *BECN1* and *ABCG2* in the tumor and paracarcinoma tissues.

RESULTS

The incidence of autophagy and the expression of *BECN1* and *ABCG2* were different in left and right colon cancer, and autophagy might be involved in the occurrence of chemotherapy resistance. Further analysis of the relationship between the expression of autophagy-related genes CDK9, *ABCG2*, and *BECN1* and the clinical features and prognosis of colorectal cancer showed that the high expression of CDK9 indicated a poor prognosis in colorectal cancer.

CONCLUSION

This study laid the foundation for further research on the combination of CDK9 inhibitors and autophagy inhibitors in the treatment of patients with CRC.

**Key Words:** Autophagy; Tumorigenesis; Tumor tissue; Paracarcinoma tissue; Expression; Left/right colon cancer

**©The** **Author(s) 2024.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Zheng L, Lu J, Kong DL. Expression of cyclin-dependent kinase 9 is positively correlated with the autophagy level in colon cancer. *World J Gastrointest Oncol* 2024; 16(2): 314-330

**URL**: https://www.wjgnet.com/1948-5204/full/v16/i2/314.htm

**DOI**: https://dx.doi.org/10.4251/wjgo.v16.i2.314

**Core Tip:** Autophagy has a dual role in tumorigenesis: inhibiting tumorigenesis under normal conditions and promoting tumor growth once formed. In colon cancer patients with liver metastasis, high cyclin-dependent kinase 9 (CDK9) expression correlated with elevated autophagy levels. Autophagy incidence and expression of *BECN1* and *ABCG2* differed between left and right colon cancer, potentially contributing to chemotherapy resistance. High CDK9 expression was associated with poor prognosis in colorectal cancer. This study provided a foundation for investigating CDK9 and autophagy inhibitors in combination therapy to enhance tumor cell sensitivity to chemotherapy.

**INTRODUCTION**

Colorectal cancer (CRC) is one of the most common malignant tumors in China, and its incidence rate is increasing every year. The latest research has confirmed that there are many differences between left-sided colon cancer and right-sided colon cancer in embryologic origin, pathogenesis, histopathology, epidemiology, epigenetics, clinical manifestations, and prognosis[1]. Some scholars postulate that left-sided colon cancer and right-sided colon cancer are two distinct diseases[2]. Therefore, the comparative study of left-sided and right-sided colon cancer is helpful to understand pathogenesis and the mechanism of progression.

Microscopically, the occurrence and development of tumors are mainly characterized by unlimited abnormal proliferation of cells. The proliferation and differentiation of cells in multicellular organisms[3,4] are regulated by the cell cycle. The main causes of tumor occurrence are cell cycle disorder and increased resistance to apoptosis. Cyclin-dependent kinases (CDKs) promote DNA synthesis and mitosis[5,6] through phosphorylation of key substrates and participate in cell cycle regulation. Abnormal activation of CDKs leads to the imbalance of the cell cycle, uncontrollable cell proliferation, and the occurrence and development of malignant tumors[7]. For example, the CDK family includes 20 kinases that contribute to cell deterioration by promoting proliferation, migration, invasion, and anti-apoptosis of cancer cells[8].

CDK9 is a key regulator of transcription and is used to continuously produce short-lived proteins to maintain the survival of cancer cells[9]. As a part of a functionally diverse group of enzymes responsible for cell cycle control and progression, CDK9 associates primarily with cyclin T1 and forms the positive transcription elongation factor b (p-TEFb) complex responsible for the regulation of transcription elongation and mRNA maturation. CDK9 can influence almost all cellular functions. Many studies have shown that the dysfunction ofCDK9 signaling is obvious in various hematologic malignancies and solid tumor cell lines, and the inhibition ofCDK9 can lead to growth suppression and apoptosis of cancer cells[10,11]. Due to the extremely critical role of CDK9 in cancer cells, inhibiting its functions has been a research hotspot, with more and more studies focusing on small, molecular inhibitors, some of which are presently in clinical trials. The search for newer CDK9 inhibitors with higher specificity and lower toxicities continues[12]. Targeting CDK9 with wogonin and related natural flavones could enhance the anticancer effect of the *BCL-2* family inhibitor ABT-263[13].

Macroautophagy, commonly known as autophagy, is the main form of cell autophagy. It sequesters proteins, lipids, or organelles that need to be degraded with a bimolecular membrane structure, forming autophagosomes. Autophagosomes can be integrated with lysosomes to form an autolysosome, which degrades the encapsulated cellular components through proteolytic enzymes and lipases in lysosomes and then recycles or excretes them. Autophagy in tumor cells is a double-edged sword. Autophagy can eliminate abnormally folded proteins and dysfunctional organelles, inhibit the stress response of cells, and ultimately prevent genome damage, thus inhibiting the occurrence of cancer[14]. On the other hand, tumor cells can utilize autophagy to promote their survival under conditions of nutritional deficiency and hypoxia[15].

The relationship between autophagy and the progression of tumorigenesis is complicated. The promotion or suppression of autophagy depends on the tumor type and environment[16]. The number of autophagosomes observed by transmission electron microscope (TEM) in cancer tissues can reflect the level of autophagy[17]. *In* *vitro* and *in* *vivo* data support the hypothesis that autophagy could enhance cancer cell drug resistance to chemotherapy, and inhibition of autophagy may increase the sensitivity of cancer cells to chemotherapy[18,19].

Evidence suggests that *BECN1* is a tumor suppressor. *BECN1* binds and activatesVP34 through a conserved domain to induce autophagy[20]. Through the positive regulators of *BECN1*, UVRAG*,* and BIF-1, the combination of *BECN1* and VP34 is enhanced, leading to an increase in autophagy and resulting in tumor inhibition[21]. Overexpression of anti-apoptotic protein BCL-2 promotes the survival of breast cancer, prostate cancer, small cell lung cancer, non-small cell lung cancer, and leukemia[22,23]. The interaction between BCL-2 and *BECN1* could be exploited to prevent autophagy[24].

Mitochondrial autophagy (also known as mitophagy) is based on selective degradation dysfunction or damaged mitochondria and plays an important role in maintaining high-quality mitochondria[25]. Regulation of this process is critical for maintaining cellular homeostasis and has been closely associated with acquired drug resistance. CDK9 may be closely associated with the regulation of mitochondrial function and mitophagy as well. It was reported that inhibition of CDK9 blocked PINK1-PRKN-mediated mitophagy in hepatocellular carcinoma by interrupting mitophagy initiation[26]. However, the relationship between autophagy and CDK9 in CRC has not been fully investigated. Therefore, elucidating the interaction between autophagy and CDK9 would be helpful for improving the efficacy of anticancer drugs in the clinical treatment of CRC.

The ATP-binding cassette transmembrane transporter superfamily is involved in the transmembrane transport of anticancer drugs, which decreases the toxicity of anticancer drugs for tumor cells. The *ABCG2* transporter mediates multidrug resistance andregulates autophagy. Under normal growth conditions, cells with high levels of *ABCG2* have a higher basic autophagy rate than cells with low levels of *ABCG2*, which could be associated with the response to stressors[27]. For example, high expression of *ABCG2* was associated with chemotherapy resistance and poor prognosis in patients with osteosarcoma[28]. In childhood leukemia and chronic lymphocytic leukemia, drug resistance to adriamycin increased after overexpression of *ABCG2*[29].

In this study, the relationship between the expression of CDK9and the incidence of autophagy in CRC was determined. We also compared the incidence of autophagy and prognosis with *ABCG2* expression in left and right colon cancers. We found that the expression of CDK9 was positively correlated with autophagyin CRC. The incidence rate of autophagy and expression of *ABCG2* in patients with liver metastasis between left and right colon cancers was different, and autophagy may be involved in the resistance to chemotherapy. We further analyzed the relationship among the expression of autophagy-related genes CDK9, *ABCG2*, and *BECN1*, the clinical features, and the prognosis of CRC.

**MATERIALS AND METHODS**

***CRC database source***

Public gene expression data and corresponding clinical annotations for transcriptome analysis were obtained from The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/; Date: March 31, 2021; Version: V29.0). RNAseq data in level 3 HTSeq FPKM format in TCGA-COAD and TCGA-READ were used. The RNAseq data in FPKM format was converted into TPM format, and log2 conversion was performed. The clinicopathological features of public data are shown in Supplementary Table 1.

***Clinical samples***

Nineteen groups of fresh tumor and paracarcinoma colon tissue derived from 19 patients were collected. Twelve patients were diagnosed with left colon cancer, and seven patients were diagnosed with right colon cancer. All patients had liver metastasis. Twenty-four groups of fresh tumor tissue and paired tissue from 24 patients were collected. Fifteen patients were diagnosed with stage IV left colon cancer, and nine patients were diagnosed with right colon cancer. The basic information of the sample group is shown in Supplementary Table 2. Fresh tissues were defined as fresh surgical tissues, soybean size 1-2, and 40-50 mg. The proportion of tumor cells was greater than 40%, and the proportion of necrotic cells was not greater than 10%. Informed consent was obtained from all subjects and/or their legal guardians.

***TEM and immunohistochemistry***

Electron microscopy samples of 24 groups of fresh tumor tissue and paracarcinoma tissue from stage IV left and right colon cancer patients were prepared according to a previously published protocol[30]. Nineteen groups of fresh tumor and paracarcinoma tissues derived from 19 patients with left and right colon cancer with liver metastasis were used for immunohistochemistry (IHC) based on protocols in our facility’s pathology department.

For TEM, tumor and paracarcinoma tissues from stage IV colon cancer patients were fixed in 2.5% glutaraldehyde, rinsed in 0.1 M phosphoric acid, and then immobilized with 1% osmic acid fixative. Dehydration included sequential steps in ethanol and acetone. Samples were embedded, solidified, and sliced into 70-nm sections. Staining was performed with 3% uranium acetate-lead citrate. Finally, observation and filming were carried out using the JEOL JEM-1230 TEM at 80 KV.

For IHC, paraffin section preparation involved tissue dehydration, transparency, wax immersion, block embedding, and sectioning. Dewaxing included xylene, 100% alcohol, and subsequent alcohol concentrations with 10-min intervals. Duration varied with temperature. For antigen repair, the tissues were washed, treated with 3% hydrogen peroxide for 10 min and then citric acid buffer before being microwaved for antigen exposure. Serum blocking involved washing with phosphate buffered saline, drying, serum addition, and incubation at 37 °C. The serum was diluted 10 times. Primary antibody was applied, and slides were stored at 4 °C overnight. Secondary antibody was applied after phosphate buffered saline washing. StreptAvidin-Biotin Complex solution was applied for 30 min at 37 °C. The slides were exposed to developer solution, and staining with hematoxylin was completed in 0.5-5.0 min. Dehydration included various alcohol concentrations and xylene. Slides were finally sealed and dried.

***CYTO-ID® autophagy detection kit***

Autophagy was analyzed by flow cytometry using the CYTO-ID® Autophagy Detection kit (Enzo Life Sciences, Farmingdale, NY, United States).

***Statistical analysis***

Gene expression and clinical data were analyzed using R (version 3.6.3). Numerical variables were expressed as median and 25th-75th percentile. Categorical variables were expressed as numbers and percentages. The Student’s *t* test was used for normally distributed data, and the Mann Whitney U test was used for comparing non-normally distributed data. The *χ*2 test was used to compare categorical data. For paired samples that met the normality test, the paired sample *t* test was used. For paired samples that did not meet the normality test, the Wilcoxon signed-rank test was used.

The median gene expression level was the cutoff point, and the expression was divided into high or low expression levels. Kaplan-Meier survival analysis was applied to evaluate the overall survival rate (OS), disease-specific survival rate (DSS), and progression-free interval (PFI) of CRC at high or low expression levels. To find the factors related to OS, DSS, and PFI, we used the Cox regression model for analysis. The area under the curve (AUC) of the time-dependent receiver operating characteristic (ROC) curve was used to evaluate the accuracy of *ABCG2*, CDK9, and *BECN1* expression levels in predicting the prognosis of patients. Autophagy pathway genes in the react database andCDK9 were imported into the string database to build protein-protein interaction (PPI) networks. CDK9 interaction genes were filtered and transferred to Cytoscape to make a PPI network. *P* values < 0.05 were considered significant.

**RESULTS**

***Expression of* CDK9 *in CRC tissues***

TCGA-COAD and TCGA-READ analyses showed that the expression of CDK9 was increased in 50 paired CRC tissues (Figure 1, Supplementary Table 1).

***Relationship between the expression of* CDK9 *and autophagy and its protein interactions***

We collected tumor tissues and paracarcinoma tissues from colon cancer patients with liver metastasis. We observed by TEM that tissues with a high level ofCDK9 had significantly higher levels of autophagy than the tissues with a low expression of CDK9 (Figure 2). We demonstrated that the expression ofCDK9 in colon cancer was positively correlated with autophagy. PPI networks of CDK9 are shown in Supplementary Figure 1. CDK9 interacts with CSNK2B, HSP90AA1, and RAPTOR, all of which have an association with the progression and prognosis of CRC[31-33].

**CDK9 *was an independent prognosis marker of CRC***

We used Cox regression analysis to determine whether CDK9 expression levels could be used to evaluate the prognosis of patients with CRC. A high expression level of CDK9was a risk factor for the prognosis of CRC that was associated with OS and DSS (all *P* < 0.050; Figure 3, Tables 1 and 2). Multivariate Cox regression analysis revealed that high expression of CDK9 was an independent prognosis marker associated with OS and DSS (all *P* < 0.050; Figure 3, Tables 1 and 2).

***Autophagy incidence and expression levels of BECN1 and ABCG2 in left and right colon cancer tissue***

We collected 24 groups of fresh tumor tissue and paired tissue from 24 patients with stage IV left and right colon cancer. We observed autophagy with a projection electron microscope and counted the positive rate of autophagy in multiple fields. The results showed that the positive rate (8/9) of autophagy in right colon cancer was significantly higher than that in left colon cancer (5/15; *χ2* = 6.993, *P* = 0.030) and paracarcinoma tissue (3/9; *χ2* = 5.844, *P* = 0.016) (Figure 4A). Primary cells were isolated from the fresh tumor tissues of colon cancer patients with liver metastasis. The CYTO-ID® autophagy detection reagent was used for staining. Flow cytometry was used to detect the formation of autophagy in the primary cancer cells. The results (Figure 4B) were consistent with the observations from electron microscopy.

We compared the expression of *BECN1* and *ABCG2* between 19 groups of fresh tumor tissue and paracarcinoma tissue from colon cancer patients with liver metastasis. We also compared the expression patterns of *BECN1* and *ABCG2* in left and right CRC. IHC results showed that there were no significant differences in the positive probability and expression level of *BECN1* between advanced colon cancer and paracarcinoma tissue. However, the positive rate of right colon cancer (72.2%, 6/7) was significantly higher than that of left colon cancer (3/12; *χ2* = 6.537; *P* = 0.011; Figure 5A). In addition, we found that compared with the paracarcinoma tissues, the right colon cancer tissue showed a high expression of *ABCG2*, while the expression level of *ABCG2* in the left colon cancer had no significant difference compared with the paracarcinoma tissues (Figure 5B).

These results suggest that the incidence of autophagy in the primary liver metastasis of left and right colon cancers is different, and it may be involved in the occurrence of chemotherapy resistance.

***Relationship between the expression levels of CDK9, ABCG2, and BECN1 and the clinical features and prognosis of CRC***

Basic information of *BECN1*, CDK9, and *ABCG2* expression levels from 644 CRC samples in relation to clinical data were analyzed (Tables 1-3 and Supplementary Table 2). The expression levels ofCDK9 were associated with tumor T stage and lymph node invasion (Table 1). The expression levels of *ABCG2* were associated with tumor N-stage and lymph node invasion (Table 2). The expression levels of *BECN1* were related to age, history of colon polyps, and lymph node invasion (Table 3). There was no correlation between CDK9 and age and *ABCG2* and age (*P* = 0.821 and *P* = 0.388, respectively). There was a weak correlation between *BECN1* and age (rho = -0.135, *P* = 0.001). There was no correlation between CDK9and tumor stage and *BECN1* and tumor stage (*P* = 0.368 and *P* = 0.884, respectively). There was a weak correlation between *ABCG2* and tumor stage (rho = 0.105, *P* = 0.009).

The Kaplan-Meier survival analysis was used to evaluate the OS, DSS, and PFI of CRC patients with high or low expression levels of *BECN1*, CDK9, and *ABCG2*. Univariate and multivariate analysis of OS, disease-free survival, and DSS for CDK9, *ABCG2*, and *BECN1* are shown in Supplementary Table 3 and Supplementary Figure 2. The high expression level of CDK9 predicted the poor prognosis of CRC (OS, DSS, and PFI were consistent and statistically significant) (Figure 3A). The high expression level of *BECN1* only predicted a poor prognosis of rectal cancer (Figure 3B and C). The high expression level of *ABCG2* only predicted a poor prognosis in colon cancer (Figure 3D).

According to the expression levels of CDK9 (Figure 6A), *BECN1* (Figure 6B), and *ABCG2* (Figure 6C), the AUC of the time-dependent ROC curve was used to evaluate the prediction accuracy of prognosis in CRC patients. The larger the AUC value, the higher the accuracy of the prediction. *ABCG2* expression levels showed the highest level of accuracy (AUC = 0.985 for rectal cancer; AUC = 0.987 for colon cancer) for the prognosis of CRC. CDK9 showed the second-highest level of accuracy for the prognosis of CRC, while *BECN1* showed a lower accuracy for the prognosis of CRC.

**DISCUSSION**

CDK9 is the catalytic kinase of p-TEFb, which is the key to the transcription elongation of most protein-coding genes[34]. Studies have shown that CDK9 is highly expressed in CRC, breast cancer, prostate cancer, and lung cancer, and it is closely related to the malignant degree of the tumors[35]. In the early stage of tumorigenesis, autophagy serves as a survival approach and quality control mechanism to prevent the occurrence of tumors and inhibit the development of tumors. However, once the tumors are formed, autophagy can be subjected to environmental pressure, which contributes to the survival and growth of the formed tumors and promotes the invasion of the cancer by promoting metastasis[36]. Few studies on the relationship between CDK9 and autophagy have been conducted.

CDK9 inhibitors promote dephosphorylation of SIRT1 and degradation of FOXO3, which is regulated by its acetylation, mediating the transcriptional repression of *FOXO3*-driven *BNIP3* and impairing the *BNIP3*-mediated stability of the PINK1 protein. Lysosomal degradation inhibitors cannot rescue mitophagy flux blocked by CDK9 inhibitors. Thus, CDK9 inhibitors inactivate the *SIRT1-FOXO3-BNIP3* axis and *PINK1-PRKN* pathway to subsequently block mitophagy initiation in hepatocellular carcinoma. CDK9 alongside *mTOR* complexes modulate translation. *TOR* complexes have recently emerged as a potential target for autophagic regulation[37]. This study confirmed that CDK9 is highly expressed in CRC and that expression of CDK9is positively correlated with autophagy in colon cancer.

*ABCG2* plays a crucial role in drug transport and cellular defense mechanisms. *In* *vitro* experiments have demonstrated that the expression of *ABCG2* can enhance cell survival and resistance to adverse conditions, such as amino acid starvation and radiation-associated cell death. These resistance mechanisms are closely associated with *ABCG2*-dependent autophagy, a cellular process that helps maintain cell homeostasis and repair damage[27]. The enhancement of autophagy depends on the overexpression of *ABCG2*[27]. The positive rate of autophagy in right colon cancer was significantly higher than that in the left colon cancer. We also found that the expression level of *ABCG2* in right colon cancer was higher than that in the paracarcinoma tissue, while there was no significant difference between the expression level of *ABCG2* in left colon cancer and the paracarcinoma tissue (Figure 5B). The root cause of chemotherapy resistance in breast cancer is closely related to cancer stem cell subsets, and their activation depends on paclitaxel-promoted autophagy[38]. It was found that rapamycin-induced autophagy could reduce the chemosensitivity of breast cancer cells to the XIAOPI formula[39].

High expression of the CDK9 marker represented a poor prognosis for patients with CRC. The expression CDK9 was upregulated in patients with papillary thyroid carcinoma, and it was associated with prognosis in these patients[40]. High expression of CDK9 is an independent marker for the poor prognosis in osteosarcoma[41]. CDK9 is also highly expressed in human ovarian cancer cell lines. Furthermore, an increase in CDK9 was significantly associated with poor prognosis in our CRC patients[10].

It was previously observed that there are differences between left and right colon cancers in molecular biological characteristics, morbidity, and response to targeted drug therapy[42]. The disease-free survival rate of resected right colon cancer and left colon cancer after radical surgery is similar, but patients with metastatic left colon cancer have a longer survival rate than patients with right colon cancer after palliative chemotherapy[2].Some data indicate that the survival rate of right colon cancer patients has not improved since 1980 compared to left colon cancer patients, and the prognosis of these right colon cancer patients is worse[43].

It has been shown that autophagy plays a dual role in cancer: Autophagy activation can promote the survival of cancer cells (protective autophagy) or autophagy can lead to the death of cancer cells (cytotoxic/nonprotective autophagy)[43]. The TEM results showed that the level of autophagy in the right colon cancer tissue was significantly higher than that in the left colon cancer tissue, which may be one of the reasons for the poor prognosis of right colon cancer compared with left colon cancer. The specific mechanism of the differences between left and right colon cancer needs further study.

**CONCLUSION**

We found that the incidence of autophagy was different between left and right colon cancers with primary liver metastasis, and autophagy might be involved in the development of chemotherapy resistance. This study has laid the foundation for further research on the combination of CDK9 inhibitors and autophagy inhibitors in the treatment of patients. The results from this study also show that tumor cell sensitivity to chemotherapy can be enhanced.

**ACKNOWLEDGEMENTS**

This work was supported by Cancer Biobank of Tianjin Medical University Cancer Institute and Hospital.

**ARTICLE HIGHLIGHTS**

***Research background***

Cyclin-dependent kinase 9 (CDK9) expression and autophagy in colorectal cancer (CRC) tissues has not been widely studied. CDK9, a key regulator of transcription, may influence the occurrence and progression of CRC. The expression of autophagy-related genes *BECN1* and drug resistance factor *ABCG2* may also play a role in CRC.

***Research motivation***

Under normal physiological conditions, autophagy can inhibit tumorigenesis, but once a tumor forms, autophagy may promote tumor growth. Therefore, understanding the relationship between autophagy and cancer, particularly how autophagy promotes tumor growth after its formation, is a key motivation for this research.

***Research objectives***

To investigate the relationship between CDK9 expression and autophagy in CRC, assess differences in autophagy between left and right colon cancers, and analyze the associations of autophagy-related genes with clinical features and prognosis.

***Research methods***

The research utilized a multi-faceted approach involving data analysis from The Cancer Genome Atlas database to study CDK9expression in CRC. We also collected fresh tumor and paracarcinoma tissues for electron microscopy, immunohistochemistry, and flow cytometry to investigate autophagy. Additionally, the study analyzed the expression of autophagy-related genes *BECN1* and *ABCG2* and their correlation with clinical features and prognosis.

***Research results***

CDK9 expression was increased in CRC tissues. CDK9 expression positively correlated with the level of autophagy in colon cancer, indicating a potential link between CDK9 and autophagy in cancer progression. The incidence of autophagy was also found to be significantly higher in right colon cancer compared to left colon cancer with primary liver metastasis. Right colon cancer displayed a higher expression of *ABCG2*, suggesting a potential mechanism for the observed differences in prognosis between left and right colon cancers. High expression of CDK9 was found to be associated with a poor prognosis in CRC, affecting overall survival, disease-specific survival, and progression-free interval. The expression of CDK9 was linked to specific clinical features such as tumor T-stage and lymph node invasion. Finally, high expressions of *ABCG2* and *BECN1* were also associated with specific clinical features, and expression levels of *ABCG2* had a high predictive accuracy for CRC prognosis.

***Research conclusions***

CDK9 expression positively correlated with the level of autophagy in colon cancer. Thus, this study has laid the foundation for further research on the combination of CDK9 inhibitors and autophagy inhibitors in the treatment of tumor patients.

***Research perspectives***

This study emphasized the significance of patient-specific treatment approaches in CRC cancer, highlighting the role of CDK9, autophagy, and drug resistance factors in prognosis. It underscored the need for combination therapies and further research to improve cancer treatment outcomes.

**REFERENCES**

1 **Lee GH**, Malietzis G, Askari A, Bernardo D, Al-Hassi HO, Clark SK. Is right-sided colon cancer different to left-sided colorectal cancer? - a systematic review. *Eur J Surg Oncol* 2015; **41**: 300-308 [PMID: 25468456 DOI: 10.1016/j.ejso.2014.11.001]

2 **Shen H**, Yang J, Huang Q, Jiang MJ, Tan YN, Fu JF, Zhu LZ, Fang XF, Yuan Y. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. *World J Gastroenterol* 2015; **21**: 6470-6478 [PMID: 26074686 DOI: 10.3748/wjg.v21.i21.6470]

3 **Tutone M**, Almerico AM. Recent advances on CDK inhibitors: An insight by means of in silico methods. *Eur J Med Chem* 2017; **142**: 300-315 [PMID: 28802482 DOI: 10.1016/j.ejmech.2017.07.067]

4 **Duronio RJ**, Xiong Y. Signaling pathways that control cell proliferation. *Cold Spring Harb Perspect Biol* 2013; **5**: a008904 [PMID: 23457258 DOI: 10.1101/cshperspect.a008904]

5 **Siemeister G**, Lücking U, Wengner AM, Lienau P, Steinke W, Schatz C, Mumberg D, Ziegelbauer K. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. *Mol Cancer Ther* 2012; **11**: 2265-2273 [PMID: 22821149 DOI: 10.1158/1535-7163.MCT-12-0286]

6 **Barnum KJ**, O'Connell MJ. Cell cycle regulation by checkpoints. *Methods Mol Biol* 2014; **1170**: 29-40 [PMID: 24906307 DOI: 10.1007/978-1-4939-0888-2\_2]

7 **Martin MP**, Endicott JA, Noble MEM. Structure-based discovery of cyclin-dependent protein kinase inhibitors. *Essays Biochem* 2017; **61**: 439-452 [PMID: 29118092 DOI: 10.1042/EBC20170040]

8 **Kretz AL**, Schaum M, Richter J, Kitzig EF, Engler CC, Leithäuser F, Henne-Bruns D, Knippschild U, Lemke J. CDK9 is a prognostic marker and therapeutic target in pancreatic cancer. *Tumour Biol* 2017; **39**: 1010428317694304 [PMID: 28231737 DOI: 10.1177/1010428317694304]

9 **Anshabo AT**, Milne R, Wang S, Albrecht H. CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents. *Front Oncol* 2021; **11**: 678559 [PMID: 34041038 DOI: 10.3389/fonc.2021.678559]

10 **Wang J**, Dean DC, Hornicek FJ, Shi H, Duan Z. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer. *FASEB J* 2019; **33**: 5990-6000 [PMID: 30726104 DOI: 10.1096/fj.201801789RR]

11 **Lee DJ**, Zeidner JF. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach. *Expert Opin Investig Drugs* 2019; **28**: 989-1001 [PMID: 31612739 DOI: 10.1080/13543784.2019.1678583]

12 **Wu T**, Qin Z, Tian Y, Wang J, Xu C, Li Z, Bian J. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. *J Med Chem* 2020; **63**: 13228-13257 [PMID: 32866383 DOI: 10.1021/acs.jmedchem.0c00744]

13 **Polier G**, Giaisi M, Köhler R, Müller WW, Lutz C, Buss EC, Krammer PH, Li-Weber M. Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263. *Int J Cancer* 2015; **136**: 688-698 [PMID: 24895203 DOI: 10.1002/ijc.29009]

14 **Klionsky DJ**, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algül H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Bánhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolomé A, Bassham DC, Bassi MT, Bast RC Jr, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR Jr, Becker C, Beckham JD, Bédard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Bénard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Böckler S, Boes M, Boesze-Battaglia K, Boise LH, Bolino A, Boman A, Bonaldo P, Bordi M, Bosch J, Botana LM, Botti J, Bou G, Bouché M, Bouchecareilh M, Boucher MJ, Boulton ME, Bouret SG, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady N, Braga VM, Brancolini C, Braus GH, Bravo-San Pedro JM, Brennan LA, Bresnick EH, Brest P, Bridges D, Bringer MA, Brini M, Brito GC, Brodin B, Brookes PS, Brown EJ, Brown K, Broxmeyer HE, Bruhat A, Brum PC, Brumell JH, Brunetti-Pierri N, Bryson-Richardson RJ, Buch S, Buchan AM, Budak H, Bulavin DV, Bultman SJ, Bultynck G, Bumbasirevic V, Burelle Y, Burke RE, Burmeister M, Bütikofer P, Caberlotto L, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calatayud S, Camougrand N, Campanella M, Campbell GR, Campbell M, Campello S, Candau R, Caniggia I, Cantoni L, Cao L, Caplan AB, Caraglia M, Cardinali C, Cardoso SM, Carew JS, Carleton LA, Carlin CR, Carloni S, Carlsson SR, Carmona-Gutierrez D, Carneiro LA, Carnevali O, Carra S, Carrier A, Carroll B, Casas C, Casas J, Cassinelli G, Castets P, Castro-Obregon S, Cavallini G, Ceccherini I, Cecconi F, Cederbaum AI, Ceña V, Cenci S, Cerella C, Cervia D, Cetrullo S, Chaachouay H, Chae HJ, Chagin AS, Chai CY, Chakrabarti G, Chamilos G, Chan EY, Chan MT, Chandra D, Chandra P, Chang CP, Chang RC, Chang TY, Chatham JC, Chatterjee S, Chauhan S, Che Y, Cheetham ME, Cheluvappa R, Chen CJ, Chen G, Chen GC, Chen G, Chen H, Chen JW, Chen JK, Chen M, Chen M, Chen P, Chen Q, Chen Q, Chen SD, Chen S, Chen SS, Chen W, Chen WJ, Chen WQ, Chen W, Chen X, Chen YH, Chen YG, Chen Y, Chen Y, Chen Y, Chen YJ, Chen YQ, Chen Y, Chen Z, Chen Z, Cheng A, Cheng CH, Cheng H, Cheong H, Cherry S, Chesney J, Cheung CH, Chevet E, Chi HC, Chi SG, Chiacchiera F, Chiang HL, Chiarelli R, Chiariello M, Chieppa M, Chin LS, Chiong M, Chiu GN, Cho DH, Cho SG, Cho WC, Cho YY, Cho YS, Choi AM, Choi EJ, Choi EK, Choi J, Choi ME, Choi SI, Chou TF, Chouaib S, Choubey D, Choubey V, Chow KC, Chowdhury K, Chu CT, Chuang TH, Chun T, Chung H, Chung T, Chung YL, Chwae YJ, Cianfanelli V, Ciarcia R, Ciechomska IA, Ciriolo MR, Cirone M, Claerhout S, Clague MJ, Clària J, Clarke PG, Clarke R, Clementi E, Cleyrat C, Cnop M, Coccia EM, Cocco T, Codogno P, Coers J, Cohen EE, Colecchia D, Coletto L, Coll NS, Colucci-Guyon E, Comincini S, Condello M, Cook KL, Coombs GH, Cooper CD, Cooper JM, Coppens I, Corasaniti MT, Corazzari M, Corbalan R, Corcelle-Termeau E, Cordero MD, Corral-Ramos C, Corti O, Cossarizza A, Costelli P, Costes S, Cotman SL, Coto-Montes A, Cottet S, Couve E, Covey LR, Cowart LA, Cox JS, Coxon FP, Coyne CB, Cragg MS, Craven RJ, Crepaldi T, Crespo JL, Criollo A, Crippa V, Cruz MT, Cuervo AM, Cuezva JM, Cui T, Cutillas PR, Czaja MJ, Czyzyk-Krzeska MF, Dagda RK, Dahmen U, Dai C, Dai W, Dai Y, Dalby KN, Dalla Valle L, Dalmasso G, D'Amelio M, Damme M, Darfeuille-Michaud A, Dargemont C, Darley-Usmar VM, Dasarathy S, Dasgupta B, Dash S, Dass CR, Davey HM, Davids LM, Dávila D, Davis RJ, Dawson TM, Dawson VL, Daza P, de Belleroche J, de Figueiredo P, de Figueiredo RC, de la Fuente J, De Martino L, De Matteis A, De Meyer GR, De Milito A, De Santi M, de Souza W, De Tata V, De Zio D, Debnath J, Dechant R, Decuypere JP, Deegan S, Dehay B, Del Bello B, Del Re DP, Delage-Mourroux R, Delbridge LM, Deldicque L, Delorme-Axford E, Deng Y, Dengjel J, Denizot M, Dent P, Der CJ, Deretic V, Derrien B, Deutsch E, Devarenne TP, Devenish RJ, Di Bartolomeo S, Di Daniele N, Di Domenico F, Di Nardo A, Di Paola S, Di Pietro A, Di Renzo L, DiAntonio A, Díaz-Araya G, Díaz-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dickey CA, Dickson RC, Diederich M, Digard P, Dikic I, Dinesh-Kumar SP, Ding C, Ding WX, Ding Z, Dini L, Distler JH, Diwan A, Djavaheri-Mergny M, Dmytruk K, Dobson RC, Doetsch V, Dokladny K, Dokudovskaya S, Donadelli M, Dong XC, Dong X, Dong Z, Donohue TM Jr, Doran KS, D'Orazi G, Dorn GW 2nd, Dosenko V, Dridi S, Drucker L, Du J, Du LL, Du L, du Toit A, Dua P, Duan L, Duann P, Dubey VK, Duchen MR, Duchosal MA, Duez H, Dugail I, Dumit VI, Duncan MC, Dunlop EA, Dunn WA Jr, Dupont N, Dupuis L, Durán RV, Durcan TM, Duvezin-Caubet S, Duvvuri U, Eapen V, Ebrahimi-Fakhari D, Echard A, Eckhart L, Edelstein CL, Edinger AL, Eichinger L, Eisenberg T, Eisenberg-Lerner A, Eissa NT, El-Deiry WS, El-Khoury V, Elazar Z, Eldar-Finkelman H, Elliott CJ, Emanuele E, Emmenegger U, Engedal N, Engelbrecht AM, Engelender S, Enserink JM, Erdmann R, Erenpreisa J, Eri R, Eriksen JL, Erman A, Escalante R, Eskelinen EL, Espert L, Esteban-Martínez L, Evans TJ, Fabri M, Fabrias G, Fabrizi C, Facchiano A, Færgeman NJ, Faggioni A, Fairlie WD, Fan C, Fan D, Fan J, Fang S, Fanto M, Fanzani A, Farkas T, Faure M, Favier FB, Fearnhead H, Federici M, Fei E, Felizardo TC, Feng H, Feng Y, Feng Y, Ferguson TA, Fernández ÁF, Fernandez-Barrena MG, Fernandez-Checa JC, Fernández-López A, Fernandez-Zapico ME, Feron O, Ferraro E, Ferreira-Halder CV, Fesus L, Feuer R, Fiesel FC, Filippi-Chiela EC, Filomeni G, Fimia GM, Fingert JH, Finkbeiner S, Finkel T, Fiorito F, Fisher PB, Flajolet M, Flamigni F, Florey O, Florio S, Floto RA, Folini M, Follo C, Fon EA, Fornai F, Fortunato F, Fraldi A, Franco R, Francois A, François A, Frankel LB, Fraser ID, Frey N, Freyssenet DG, Frezza C, Friedman SL, Frigo DE, Fu D, Fuentes JM, Fueyo J, Fujitani Y, Fujiwara Y, Fujiya M, Fukuda M, Fulda S, Fusco C, Gabryel B, Gaestel M, Gailly P, Gajewska M, Galadari S, Galili G, Galindo I, Galindo MF, Galliciotti G, Galluzzi L, Galluzzi L, Galy V, Gammoh N, Gandy S, Ganesan AK, Ganesan S, Ganley IG, Gannagé M, Gao FB, Gao F, Gao JX, García Nannig L, García Véscovi E, Garcia-Macía M, Garcia-Ruiz C, Garg AD, Garg PK, Gargini R, Gassen NC, Gatica D, Gatti E, Gavard J, Gavathiotis E, Ge L, Ge P, Ge S, Gean PW, Gelmetti V, Genazzani AA, Geng J, Genschik P, Gerner L, Gestwicki JE, Gewirtz DA, Ghavami S, Ghigo E, Ghosh D, Giammarioli AM, Giampieri F, Giampietri C, Giatromanolaki A, Gibbings DJ, Gibellini L, Gibson SB, Ginet V, Giordano A, Giorgini F, Giovannetti E, Girardin SE, Gispert S, Giuliano S, Gladson CL, Glavic A, Gleave M, Godefroy N, Gogal RM Jr, Gokulan K, Goldman GH, Goletti D, Goligorsky MS, Gomes AV, Gomes LC, Gomez H, Gomez-Manzano C, Gómez-Sánchez R, Gonçalves DA, Goncu E, Gong Q, Gongora C, Gonzalez CB, Gonzalez-Alegre P, Gonzalez-Cabo P, González-Polo RA, Goping IS, Gorbea C, Gorbunov NV, Goring DR, Gorman AM, Gorski SM, Goruppi S, Goto-Yamada S, Gotor C, Gottlieb RA, Gozes I, Gozuacik D, Graba Y, Graef M, Granato GE, Grant GD, Grant S, Gravina GL, Green DR, Greenhough A, Greenwood MT, Grimaldi B, Gros F, Grose C, Groulx JF, Gruber F, Grumati P, Grune T, Guan JL, Guan KL, Guerra B, Guillen C, Gulshan K, Gunst J, Guo C, Guo L, Guo M, Guo W, Guo XG, Gust AA, Gustafsson ÅB, Gutierrez E, Gutierrez MG, Gwak HS, Haas A, Haber JE, Hadano S, Hagedorn M, Hahn DR, Halayko AJ, Hamacher-Brady A, Hamada K, Hamai A, Hamann A, Hamasaki M, Hamer I, Hamid Q, Hammond EM, Han F, Han W, Handa JT, Hanover JA, Hansen M, Harada M, Harhaji-Trajkovic L, Harper JW, Harrath AH, Harris AL, Harris J, Hasler U, Hasselblatt P, Hasui K, Hawley RG, Hawley TS, He C, He CY, He F, He G, He RR, He XH, He YW, He YY, Heath JK, Hébert MJ, Heinzen RA, Helgason GV, Hensel M, Henske EP, Her C, Herman PK, Hernández A, Hernandez C, Hernández-Tiedra S, Hetz C, Hiesinger PR, Higaki K, Hilfiker S, Hill BG, Hill JA, Hill WD, Hino K, Hofius D, Hofman P, Höglinger GU, Höhfeld J, Holz MK, Hong Y, Hood DA, Hoozemans JJ, Hoppe T, Hsu C, Hsu CY, Hsu LC, Hu D, Hu G, Hu HM, Hu H, Hu MC, Hu YC, Hu ZW, Hua F, Hua Y, Huang C, Huang HL, Huang KH, Huang KY, Huang S, Huang S, Huang WP, Huang YR, Huang Y, Huang Y, Huber TB, Huebbe P, Huh WK, Hulmi JJ, Hur GM, Hurley JH, Husak Z, Hussain SN, Hussain S, Hwang JJ, Hwang S, Hwang TI, Ichihara A, Imai Y, Imbriano C, Inomata M, Into T, Iovane V, Iovanna JL, Iozzo RV, Ip NY, Irazoqui JE, Iribarren P, Isaka Y, Isakovic AJ, Ischiropoulos H, Isenberg JS, Ishaq M, Ishida H, Ishii I, Ishmael JE, Isidoro C, Isobe K, Isono E, Issazadeh-Navikas S, Itahana K, Itakura E, Ivanov AI, Iyer AK, Izquierdo JM, Izumi Y, Izzo V, Jäättelä M, Jaber N, Jackson DJ, Jackson WT, Jacob TG, Jacques TS, Jagannath C, Jain A, Jana NR, Jang BK, Jani A, Janji B, Jannig PR, Jansson PJ, Jean S, Jendrach M, Jeon JH, Jessen N, Jeung EB, Jia K, Jia L, Jiang H, Jiang H, Jiang L, Jiang T, Jiang X, Jiang X, Jiang X, Jiang Y, Jiang Y, Jiménez A, Jin C, Jin H, Jin L, Jin M, Jin S, Jinwal UK, Jo EK, Johansen T, Johnson DE, Johnson GV, Johnson JD, Jonasch E, Jones C, Joosten LA, Jordan J, Joseph AM, Joseph B, Joubert AM, Ju D, Ju J, Juan HF, Juenemann K, Juhász G, Jung HS, Jung JU, Jung YK, Jungbluth H, Justice MJ, Jutten B, Kaakoush NO, Kaarniranta K, Kaasik A, Kabuta T, Kaeffer B, Kågedal K, Kahana A, Kajimura S, Kakhlon O, Kalia M, Kalvakolanu DV, Kamada Y, Kambas K, Kaminskyy VO, Kampinga HH, Kandouz M, Kang C, Kang R, Kang TC, Kanki T, Kanneganti TD, Kanno H, Kanthasamy AG, Kantorow M, Kaparakis-Liaskos M, Kapuy O, Karantza V, Karim MR, Karmakar P, Kaser A, Kaushik S, Kawula T, Kaynar AM, Ke PY, Ke ZJ, Kehrl JH, Keller KE, Kemper JK, Kenworthy AK, Kepp O, Kern A, Kesari S, Kessel D, Ketteler R, Kettelhut Ido C, Khambu B, Khan MM, Khandelwal VK, Khare S, Kiang JG, Kiger AA, Kihara A, Kim AL, Kim CH, Kim DR, Kim DH, Kim EK, Kim HY, Kim HR, Kim JS, Kim JH, Kim JC, Kim JH, Kim KW, Kim MD, Kim MM, Kim PK, Kim SW, Kim SY, Kim YS, Kim Y, Kimchi A, Kimmelman AC, Kimura T, King JS, Kirkegaard K, Kirkin V, Kirshenbaum LA, Kishi S, Kitajima Y, Kitamoto K, Kitaoka Y, Kitazato K, Kley RA, Klimecki WT, Klinkenberg M, Klucken J, Knævelsrud H, Knecht E, Knuppertz L, Ko JL, Kobayashi S, Koch JC, Koechlin-Ramonatxo C, Koenig U, Koh YH, Köhler K, Kohlwein SD, Koike M, Komatsu M, Kominami E, Kong D, Kong HJ, Konstantakou EG, Kopp BT, Korcsmaros T, Korhonen L, Korolchuk VI, Koshkina NV, Kou Y, Koukourakis MI, Koumenis C, Kovács AL, Kovács T, Kovacs WJ, Koya D, Kraft C, Krainc D, Kramer H, Kravic-Stevovic T, Krek W, Kretz-Remy C, Krick R, Krishnamurthy M, Kriston-Vizi J, Kroemer G, Kruer MC, Kruger R, Ktistakis NT, Kuchitsu K, Kuhn C, Kumar AP, Kumar A, Kumar A, Kumar D, Kumar D, Kumar R, Kumar S, Kundu M, Kung HJ, Kuno A, Kuo SH, Kuret J, Kurz T, Kwok T, Kwon TK, Kwon YT, Kyrmizi I, La Spada AR, Lafont F, Lahm T, Lakkaraju A, Lam T, Lamark T, Lancel S, Landowski TH, Lane DJ, Lane JD, Lanzi C, Lapaquette P, Lapierre LR, Laporte J, Laukkarinen J, Laurie GW, Lavandero S, Lavie L, LaVoie MJ, Law BY, Law HK, Law KB, Layfield R, Lazo PA, Le Cam L, Le Roch KG, Le Stunff H, Leardkamolkarn V, Lecuit M, Lee BH, Lee CH, Lee EF, Lee GM, Lee HJ, Lee H, Lee JK, Lee J, Lee JH, Lee JH, Lee M, Lee MS, Lee PJ, Lee SW, Lee SJ, Lee SJ, Lee SY, Lee SH, Lee SS, Lee SJ, Lee S, Lee YR, Lee YJ, Lee YH, Leeuwenburgh C, Lefort S, Legouis R, Lei J, Lei QY, Leib DA, Leibowitz G, Lekli I, Lemaire SD, Lemasters JJ, Lemberg MK, Lemoine A, Leng S, Lenz G, Lenzi P, Lerman LO, Lettieri Barbato D, Leu JI, Leung HY, Levine B, Lewis PA, Lezoualc'h F, Li C, Li F, Li FJ, Li J, Li K, Li L, Li M, Li M, Li Q, Li R, Li S, Li W, Li W, Li X, Li Y, Lian J, Liang C, Liang Q, Liao Y, Liberal J, Liberski PP, Lie P, Lieberman AP, Lim HJ, Lim KL, Lim K, Lima RT, Lin CS, Lin CF, Lin F, Lin F, Lin FC, Lin K, Lin KH, Lin PH, Lin T, Lin WW, Lin YS, Lin Y, Linden R, Lindholm D, Lindqvist LM, Lingor P, Linkermann A, Liotta LA, Lipinski MM, Lira VA, Lisanti MP, Liton PB, Liu B, Liu C, Liu CF, Liu F, Liu HJ, Liu J, Liu JJ, Liu JL, Liu K, Liu L, Liu L, Liu Q, Liu RY, Liu S, Liu S, Liu W, Liu XD, Liu X, Liu XH, Liu X, Liu X, Liu X, Liu Y, Liu Y, Liu Z, Liu Z, Liuzzi JP, Lizard G, Ljujic M, Lodhi IJ, Logue SE, Lokeshwar BL, Long YC, Lonial S, Loos B, López-Otín C, López-Vicario C, Lorente M, Lorenzi PL, Lõrincz P, Los M, Lotze MT, Lovat PE, Lu B, Lu B, Lu J, Lu Q, Lu SM, Lu S, Lu Y, Luciano F, Luckhart S, Lucocq JM, Ludovico P, Lugea A, Lukacs NW, Lum JJ, Lund AH, Luo H, Luo J, Luo S, Luparello C, Lyons T, Ma J, Ma Y, Ma Y, Ma Z, Machado J, Machado-Santelli GM, Macian F, MacIntosh GC, MacKeigan JP, Macleod KF, MacMicking JD, MacMillan-Crow LA, Madeo F, Madesh M, Madrigal-Matute J, Maeda A, Maeda T, Maegawa G, Maellaro E, Maes H, Magariños M, Maiese K, Maiti TK, Maiuri L, Maiuri MC, Maki CG, Malli R, Malorni W, Maloyan A, Mami-Chouaib F, Man N, Mancias JD, Mandelkow EM, Mandell MA, Manfredi AA, Manié SN, Manzoni C, Mao K, Mao Z, Mao ZW, Marambaud P, Marconi AM, Marelja Z, Marfe G, Margeta M, Margittai E, Mari M, Mariani FV, Marin C, Marinelli S, Mariño G, Markovic I, Marquez R, Martelli AM, Martens S, Martin KR, Martin SJ, Martin S, Martin-Acebes MA, Martín-Sanz P, Martinand-Mari C, Martinet W, Martinez J, Martinez-Lopez N, Martinez-Outschoorn U, Martínez-Velázquez M, Martinez-Vicente M, Martins WK, Mashima H, Mastrianni JA, Matarese G, Matarrese P, Mateo R, Matoba S, Matsumoto N, Matsushita T, Matsuura A, Matsuzawa T, Mattson MP, Matus S, Maugeri N, Mauvezin C, Mayer A, Maysinger D, Mazzolini GD, McBrayer MK, McCall K, McCormick C, McInerney GM, McIver SC, McKenna S, McMahon JJ, McNeish IA, Mechta-Grigoriou F, Medema JP, Medina DL, Megyeri K, Mehrpour M, Mehta JL, Mei Y, Meier UC, Meijer AJ, Meléndez A, Melino G, Melino S, de Melo EJ, Mena MA, Meneghini MD, Menendez JA, Menezes R, Meng L, Meng LH, Meng S, Menghini R, Menko AS, Menna-Barreto RF, Menon MB, Meraz-Ríos MA, Merla G, Merlini L, Merlot AM, Meryk A, Meschini S, Meyer JN, Mi MT, Miao CY, Micale L, Michaeli S, Michiels C, Migliaccio AR, Mihailidou AS, Mijaljica D, Mikoshiba K, Milan E, Miller-Fleming L, Mills GB, Mills IG, Minakaki G, Minassian BA, Ming XF, Minibayeva F, Minina EA, Mintern JD, Minucci S, Miranda-Vizuete A, Mitchell CH, Miyamoto S, Miyazawa K, Mizushima N, Mnich K, Mograbi B, Mohseni S, Moita LF, Molinari M, Molinari M, Møller AB, Mollereau B, Mollinedo F, Mongillo M, Monick MM, Montagnaro S, Montell C, Moore DJ, Moore MN, Mora-Rodriguez R, Moreira PI, Morel E, Morelli MB, Moreno S, Morgan MJ, Moris A, Moriyasu Y, Morrison JL, Morrison LA, Morselli E, Moscat J, Moseley PL, Mostowy S, Motori E, Mottet D, Mottram JC, Moussa CE, Mpakou VE, Mukhtar H, Mulcahy Levy JM, Muller S, Muñoz-Moreno R, Muñoz-Pinedo C, Münz C, Murphy ME, Murray JT, Murthy A, Mysorekar IU, Nabi IR, Nabissi M, Nader GA, Nagahara Y, Nagai Y, Nagata K, Nagelkerke A, Nagy P, Naidu SR, Nair S, Nakano H, Nakatogawa H, Nanjundan M, Napolitano G, Naqvi NI, Nardacci R, Narendra DP, Narita M, Nascimbeni AC, Natarajan R, Navegantes LC, Nawrocki ST, Nazarko TY, Nazarko VY, Neill T, Neri LM, Netea MG, Netea-Maier RT, Neves BM, Ney PA, Nezis IP, Nguyen HT, Nguyen HP, Nicot AS, Nilsen H, Nilsson P, Nishimura M, Nishino I, Niso-Santano M, Niu H, Nixon RA, Njar VC, Noda T, Noegel AA, Nolte EM, Norberg E, Norga KK, Noureini SK, Notomi S, Notterpek L, Nowikovsky K, Nukina N, Nürnberger T, O'Donnell VB, O'Donovan T, O'Dwyer PJ, Oehme I, Oeste CL, Ogawa M, Ogretmen B, Ogura Y, Oh YJ, Ohmuraya M, Ohshima T, Ojha R, Okamoto K, Okazaki T, Oliver FJ, Ollinger K, Olsson S, Orban DP, Ordonez P, Orhon I, Orosz L, O'Rourke EJ, Orozco H, Ortega AL, Ortona E, Osellame LD, Oshima J, Oshima S, Osiewacz HD, Otomo T, Otsu K, Ou JH, Outeiro TF, Ouyang DY, Ouyang H, Overholtzer M, Ozbun MA, Ozdinler PH, Ozpolat B, Pacelli C, Paganetti P, Page G, Pages G, Pagnini U, Pajak B, Pak SC, Pakos-Zebrucka K, Pakpour N, Palková Z, Palladino F, Pallauf K, Pallet N, Palmieri M, Paludan SR, Palumbo C, Palumbo S, Pampliega O, Pan H, Pan W, Panaretakis T, Pandey A, Pantazopoulou A, Papackova Z, Papademetrio DL, Papassideri I, Papini A, Parajuli N, Pardo J, Parekh VV, Parenti G, Park JI, Park J, Park OK, Parker R, Parlato R, Parys JB, Parzych KR, Pasquet JM, Pasquier B, Pasumarthi KB, Patschan D, Patterson C, Pattingre S, Pattison S, Pause A, Pavenstädt H, Pavone F, Pedrozo Z, Peña FJ, Peñalva MA, Pende M, Peng J, Penna F, Penninger JM, Pensalfini A, Pepe S, Pereira GJ, Pereira PC, Pérez-de la Cruz V, Pérez-Pérez ME, Pérez-Rodríguez D, Pérez-Sala D, Perier C, Perl A, Perlmutter DH, Perrotta I, Pervaiz S, Pesonen M, Pessin JE, Peters GJ, Petersen M, Petrache I, Petrof BJ, Petrovski G, Phang JM, Piacentini M, Pierdominici M, Pierre P, Pierrefite-Carle V, Pietrocola F, Pimentel-Muiños FX, Pinar M, Pineda B, Pinkas-Kramarski R, Pinti M, Pinton P, Piperdi B, Piret JM, Platanias LC, Platta HW, Plowey ED, Pöggeler S, Poirot M, Polčic P, Poletti A, Poon AH, Popelka H, Popova B, Poprawa I, Poulose SM, Poulton J, Powers SK, Powers T, Pozuelo-Rubio M, Prak K, Prange R, Prescott M, Priault M, Prince S, Proia RL, Proikas-Cezanne T, Prokisch H, Promponas VJ, Przyklenk K, Puertollano R, Pugazhenthi S, Puglielli L, Pujol A, Puyal J, Pyeon D, Qi X, Qian WB, Qin ZH, Qiu Y, Qu Z, Quadrilatero J, Quinn F, Raben N, Rabinowich H, Radogna F, Ragusa MJ, Rahmani M, Raina K, Ramanadham S, Ramesh R, Rami A, Randall-Demllo S, Randow F, Rao H, Rao VA, Rasmussen BB, Rasse TM, Ratovitski EA, Rautou PE, Ray SK, Razani B, Reed BH, Reggiori F, Rehm M, Reichert AS, Rein T, Reiner DJ, Reits E, Ren J, Ren X, Renna M, Reusch JE, Revuelta JL, Reyes L, Rezaie AR, Richards RI, Richardson DR, Richetta C, Riehle MA, Rihn BH, Rikihisa Y, Riley BE, Rimbach G, Rippo MR, Ritis K, Rizzi F, Rizzo E, Roach PJ, Robbins J, Roberge M, Roca G, Roccheri MC, Rocha S, Rodrigues CMP, Rodríguez CI, de Cordoba SR, Rodriguez-Muela N, Roelofs J, Rogov VV, Rohn TT, Rohrer B, Romanelli D, Romani L, Romano PS, Roncero MI, Rosa JL, Rosello A, Rosen KV, Rosenstiel P, Rost-Roszkowska M, Roth KA, Roué G, Rouis M, Rouschop KM, Ruan DT, Ruano D, Rubinsztein DC, Rucker EB 3rd, Rudich A, Rudolf E, Rudolf R, Ruegg MA, Ruiz-Roldan C, Ruparelia AA, Rusmini P, Russ DW, Russo GL, Russo G, Russo R, Rusten TE, Ryabovol V, Ryan KM, Ryter SW, Sabatini DM, Sacher M, Sachse C, Sack MN, Sadoshima J, Saftig P, Sagi-Eisenberg R, Sahni S, Saikumar P, Saito T, Saitoh T, Sakakura K, Sakoh-Nakatogawa M, Sakuraba Y, Salazar-Roa M, Salomoni P, Saluja AK, Salvaterra PM, Salvioli R, Samali A, Sanchez AM, Sánchez-Alcázar JA, Sanchez-Prieto R, Sandri M, Sanjuan MA, Santaguida S, Santambrogio L, Santoni G, Dos Santos CN, Saran S, Sardiello M, Sargent G, Sarkar P, Sarkar S, Sarrias MR, Sarwal MM, Sasakawa C, Sasaki M, Sass M, Sato K, Sato M, Satriano J, Savaraj N, Saveljeva S, Schaefer L, Schaible UE, Scharl M, Schatzl HM, Schekman R, Scheper W, Schiavi A, Schipper HM, Schmeisser H, Schmidt J, Schmitz I, Schneider BE, Schneider EM, Schneider JL, Schon EA, Schönenberger MJ, Schönthal AH, Schorderet DF, Schröder B, Schuck S, Schulze RJ, Schwarten M, Schwarz TL, Sciarretta S, Scotto K, Scovassi AI, Screaton RA, Screen M, Seca H, Sedej S, Segatori L, Segev N, Seglen PO, Seguí-Simarro JM, Segura-Aguilar J, Seki E, Sell C, Seiliez I, Semenkovich CF, Semenza GL, Sen U, Serra AL, Serrano-Puebla A, Sesaki H, Setoguchi T, Settembre C, Shacka JJ, Shajahan-Haq AN, Shapiro IM, Sharma S, She H, Shen CK, Shen CC, Shen HM, Shen S, Shen W, Sheng R, Sheng X, Sheng ZH, Shepherd TG, Shi J, Shi Q, Shi Q, Shi Y, Shibutani S, Shibuya K, Shidoji Y, Shieh JJ, Shih CM, Shimada Y, Shimizu S, Shin DW, Shinohara ML, Shintani M, Shintani T, Shioi T, Shirabe K, Shiri-Sverdlov R, Shirihai O, Shore GC, Shu CW, Shukla D, Sibirny AA, Sica V, Sigurdson CJ, Sigurdsson EM, Sijwali PS, Sikorska B, Silveira WA, Silvente-Poirot S, Silverman GA, Simak J, Simmet T, Simon AK, Simon HU, Simone C, Simons M, Simonsen A, Singh R, Singh SV, Singh SK, Sinha D, Sinha S, Sinicrope FA, Sirko A, Sirohi K, Sishi BJ, Sittler A, Siu PM, Sivridis E, Skwarska A, Slack R, Slaninová I, Slavov N, Smaili SS, Smalley KS, Smith DR, Soenen SJ, Soleimanpour SA, Solhaug A, Somasundaram K, Son JH, Sonawane A, Song C, Song F, Song HK, Song JX, Song W, Soo KY, Sood AK, Soong TW, Soontornniyomkij V, Sorice M, Sotgia F, Soto-Pantoja DR, Sotthibundhu A, Sousa MJ, Spaink HP, Span PN, Spang A, Sparks JD, Speck PG, Spector SA, Spies CD, Springer W, Clair DS, Stacchiotti A, Staels B, Stang MT, Starczynowski DT, Starokadomskyy P, Steegborn C, Steele JW, Stefanis L, Steffan J, Stellrecht CM, Stenmark H, Stepkowski TM, Stern ST, Stevens C, Stockwell BR, Stoka V, Storchova Z, Stork B, Stratoulias V, Stravopodis DJ, Strnad P, Strohecker AM, Ström AL, Stromhaug P, Stulik J, Su YX, Su Z, Subauste CS, Subramaniam S, Sue CM, Suh SW, Sui X, Sukseree S, Sulzer D, Sun FL, Sun J, Sun J, Sun SY, Sun Y, Sun Y, Sun Y, Sundaramoorthy V, Sung J, Suzuki H, Suzuki K, Suzuki N, Suzuki T, Suzuki YJ, Swanson MS, Swanton C, Swärd K, Swarup G, Sweeney ST, Sylvester PW, Szatmari Z, Szegezdi E, Szlosarek PW, Taegtmeyer H, Tafani M, Taillebourg E, Tait SW, Takacs-Vellai K, Takahashi Y, Takáts S, Takemura G, Takigawa N, Talbot NJ, Tamagno E, Tamburini J, Tan CP, Tan L, Tan ML, Tan M, Tan YJ, Tanaka K, Tanaka M, Tang D, Tang D, Tang G, Tanida I, Tanji K, Tannous BA, Tapia JA, Tasset-Cuevas I, Tatar M, Tavassoly I, Tavernarakis N, Taylor A, Taylor GS, Taylor GA, Taylor JP, Taylor MJ, Tchetina EV, Tee AR, Teixeira-Clerc F, Telang S, Tencomnao T, Teng BB, Teng RJ, Terro F, Tettamanti G, Theiss AL, Theron AE, Thomas KJ, Thomé MP, Thomes PG, Thorburn A, Thorner J, Thum T, Thumm M, Thurston TL, Tian L, Till A, Ting JP, Titorenko VI, Toker L, Toldo S, Tooze SA, Topisirovic I, Torgersen ML, Torosantucci L, Torriglia A, Torrisi MR, Tournier C, Towns R, Trajkovic V, Travassos LH, Triola G, Tripathi DN, Trisciuoglio D, Troncoso R, Trougakos IP, Truttmann AC, Tsai KJ, Tschan MP, Tseng YH, Tsukuba T, Tsung A, Tsvetkov AS, Tu S, Tuan HY, Tucci M, Tumbarello DA, Turk B, Turk V, Turner RF, Tveita AA, Tyagi SC, Ubukata M, Uchiyama Y, Udelnow A, Ueno T, Umekawa M, Umemiya-Shirafuji R, Underwood BR, Ungermann C, Ureshino RP, Ushioda R, Uversky VN, Uzcátegui NL, Vaccari T, Vaccaro MI, Váchová L, Vakifahmetoglu-Norberg H, Valdor R, Valente EM, Vallette F, Valverde AM, Van den Berghe G, Van Den Bosch L, van den Brink GR, van der Goot FG, van der Klei IJ, van der Laan LJ, van Doorn WG, van Egmond M, van Golen KL, Van Kaer L, van Lookeren Campagne M, Vandenabeele P, Vandenberghe W, Vanhorebeek I, Varela-Nieto I, Vasconcelos MH, Vasko R, Vavvas DG, Vega-Naredo I, Velasco G, Velentzas AD, Velentzas PD, Vellai T, Vellenga E, Vendelbo MH, Venkatachalam K, Ventura N, Ventura S, Veras PS, Verdier M, Vertessy BG, Viale A, Vidal M, Vieira HL, Vierstra RD, Vigneswaran N, Vij N, Vila M, Villar M, Villar VH, Villarroya J, Vindis C, Viola G, Viscomi MT, Vitale G, Vogl DT, Voitsekhovskaja OV, von Haefen C, von Schwarzenberg K, Voth DE, Vouret-Craviari V, Vuori K, Vyas JM, Waeber C, Walker CL, Walker MJ, Walter J, Wan L, Wan X, Wang B, Wang C, Wang CY, Wang C, Wang C, Wang C, Wang D, Wang F, Wang F, Wang G, Wang HJ, Wang H, Wang HG, Wang H, Wang HD, Wang J, Wang J, Wang M, Wang MQ, Wang PY, Wang P, Wang RC, Wang S, Wang TF, Wang X, Wang XJ, Wang XW, Wang X, Wang X, Wang Y, Wang Y, Wang Y, Wang YJ, Wang Y, Wang Y, Wang YT, Wang Y, Wang ZN, Wappner P, Ward C, Ward DM, Warnes G, Watada H, Watanabe Y, Watase K, Weaver TE, Weekes CD, Wei J, Weide T, Weihl CC, Weindl G, Weis SN, Wen L, Wen X, Wen Y, Westermann B, Weyand CM, White AR, White E, Whitton JL, Whitworth AJ, Wiels J, Wild F, Wildenberg ME, Wileman T, Wilkinson DS, Wilkinson S, Willbold D, Williams C, Williams K, Williamson PR, Winklhofer KF, Witkin SS, Wohlgemuth SE, Wollert T, Wolvetang EJ, Wong E, Wong GW, Wong RW, Wong VK, Woodcock EA, Wright KL, Wu C, Wu D, Wu GS, Wu J, Wu J, Wu M, Wu M, Wu S, Wu WK, Wu Y, Wu Z, Xavier CP, Xavier RJ, Xia GX, Xia T, Xia W, Xia Y, Xiao H, Xiao J, Xiao S, Xiao W, Xie CM, Xie Z, Xie Z, Xilouri M, Xiong Y, Xu C, Xu C, Xu F, Xu H, Xu H, Xu J, Xu J, Xu J, Xu L, Xu X, Xu Y, Xu Y, Xu ZX, Xu Z, Xue Y, Yamada T, Yamamoto A, Yamanaka K, Yamashina S, Yamashiro S, Yan B, Yan B, Yan X, Yan Z, Yanagi Y, Yang DS, Yang JM, Yang L, Yang M, Yang PM, Yang P, Yang Q, Yang W, Yang WY, Yang X, Yang Y, Yang Y, Yang Z, Yang Z, Yao MC, Yao PJ, Yao X, Yao Z, Yao Z, Yasui LS, Ye M, Yedvobnick B, Yeganeh B, Yeh ES, Yeyati PL, Yi F, Yi L, Yin XM, Yip CK, Yoo YM, Yoo YH, Yoon SY, Yoshida K, Yoshimori T, Young KH, Yu H, Yu JJ, Yu JT, Yu J, Yu L, Yu WH, Yu XF, Yu Z, Yuan J, Yuan ZM, Yue BY, Yue J, Yue Z, Zacks DN, Zacksenhaus E, Zaffaroni N, Zaglia T, Zakeri Z, Zecchini V, Zeng J, Zeng M, Zeng Q, Zervos AS, Zhang DD, Zhang F, Zhang G, Zhang GC, Zhang H, Zhang H, Zhang H, Zhang H, Zhang J, Zhang J, Zhang J, Zhang J, Zhang JP, Zhang L, Zhang L, Zhang L, Zhang L, Zhang MY, Zhang X, Zhang XD, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhao M, Zhao WL, Zhao X, Zhao YG, Zhao Y, Zhao Y, Zhao YX, Zhao Z, Zhao ZJ, Zheng D, Zheng XL, Zheng X, Zhivotovsky B, Zhong Q, Zhou GZ, Zhou G, Zhou H, Zhou SF, Zhou XJ, Zhu H, Zhu H, Zhu WG, Zhu W, Zhu XF, Zhu Y, Zhuang SM, Zhuang X, Ziparo E, Zois CE, Zoladek T, Zong WX, Zorzano A, Zughaier SM. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy* 2016; **12**: 1-222 [PMID: 26799652 DOI: 10.1080/15548627.2015.1100356]

15 **Hayashi-Nishino M**, Fujita N, Noda T, Yamaguchi A, Yoshimori T, Yamamoto A. A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation. *Nat Cell Biol* 2009; **11**: 1433-1437 [PMID: 19898463 DOI: 10.1038/ncb1991]

16 **Wilde L**, Tanson K, Curry J, Martinez-Outschoorn U. Autophagy in cancer: a complex relationship. *Biochem J* 2018; **475**: 1939-1954 [PMID: 29891531 DOI: 10.1042/BCJ20170847]

17 **Chakraborty J**, Caicci F, Roy M, Ziviani E. Investigating mitochondrial autophagy by routine transmission electron microscopy: Seeing is believing? *Pharmacol Res* 2020; **160**: 105097 [PMID: 32739423 DOI: 10.1016/j.phrs.2020.105097]

18 **Hu YL**, Jahangiri A, Delay M, Aghi MK. Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. *Cancer Res* 2012; **72**: 4294-4299 [PMID: 22915758 DOI: 10.1158/0008-5472.CAN-12-1076]

19 **Buchser WJ**, Laskow TC, Pavlik PJ, Lin HM, Lotze MT. Cell-mediated autophagy promotes cancer cell survival. *Cancer Res* 2012; **72**: 2970-2979 [PMID: 22505650 DOI: 10.1158/0008-5472.CAN-11-3396]

20 **Singh SS**, Vats S, Chia AY, Tan TZ, Deng S, Ong MS, Arfuso F, Yap CT, Goh BC, Sethi G, Huang RY, Shen HM, Manjithaya R, Kumar AP. Dual role of autophagy in hallmarks of cancer. *Oncogene* 2018; **37**: 1142-1158 [PMID: 29255248 DOI: 10.1038/s41388-017-0046-6]

21 **Takahashi Y**, Coppola D, Matsushita N, Cualing HD, Sun M, Sato Y, Liang C, Jung JU, Cheng JQ, Mulé JJ, Pledger WJ, Wang HG. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. *Nat Cell Biol* 2007; **9**: 1142-1151 [PMID: 17891140 DOI: 10.1038/ncb1634]

22 **Fernald K**, Kurokawa M. Evading apoptosis in cancer. *Trends Cell Biol* 2013; **23**: 620-633 [PMID: 23958396 DOI: 10.1016/j.tcb.2013.07.006]

23 **Hanahan D**, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; **144**: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]

24 **Pattingre S**, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. *Cell* 2005; **122**: 927-939 [PMID: 16179260 DOI: 10.1016/j.cell.2005.07.002]

25 **Li A**, Gao M, Liu B, Qin Y, Chen L, Liu H, Wu H, Gong G. Mitochondrial autophagy: molecular mechanisms and implications for cardiovascular disease. *Cell Death Dis* 2022; **13**: 444 [PMID: 35534453 DOI: 10.1038/s41419-022-04906-6]

26 **Yao J**, Wang J, Xu Y, Guo Q, Sun Y, Liu J, Li S, Guo Y, Wei L. CDK9 inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma. *Autophagy* 2022; **18**: 1879-1897 [PMID: 34890308 DOI: 10.1080/15548627.2021.2007027]

27 **Ding R**, Jin S, Pabon K, Scotto KW. A role for *ABCG2* beyond drug transport: Regulation of autophagy. *Autophagy* 2016; **12**: 737-751 [PMID: 26983466 DOI: 10.1080/15548627.2016.1155009]

28 **Shu H**, Yuan B, Huang Y, Wang L, He B, Sun Q, Sun L. High expression of *ABCG2* is associated with chemotherapy resistance of osteosarcoma. *J Orthop Surg Res* 2021; **16**: 85 [PMID: 33509236 DOI: 10.1186/s13018-021-02204-z]

29 **Svirnovski AI**, Shman TV, Serhiyenka TF, Savitski VP, Smolnikova VV, Fedasenka UU. ABCB1 and *ABCG2* proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. *Hematology* 2009; **14**: 204-212 [PMID: 19635183 DOI: 10.1179/102453309X426218]

30 **Arai R**, Waguri S. Improved Electron Microscopy Fixation Methods for Tracking Autophagy-Associated Membranes in Cultured Mammalian Cells. *Methods Mol Biol* 2019; **1880**: 211-221 [PMID: 30610699 DOI: 10.1007/978-1-4939-8873-0\_13]

31 **Yu S**, Hu Q, Fan K, Yang C, Gao Y. CSNK2B contributes to colorectal cancer cell proliferation by activating the mTOR signaling. *J Cell Commun Signal* 2021; **15**: 383-392 [PMID: 33928514 DOI: 10.1007/s12079-021-00619-1]

32 **Zhang M**, Peng Y, Yang Z, Zhang H, Xu C, Liu L, Zhao Q, Wu J, Wang H, Liu J. DAB2IP down-regulates HSP90AA1 to inhibit the malignant biological behaviors of colorectal cancer. *BMC Cancer* 2022; **22**: 561 [PMID: 35590292 DOI: 10.1186/s12885-022-09596-z]

33 **Wang T**, Zhang WS, Wang ZX, Wu ZW, Du BB, Li LY, Chen YF, Yang XF, Hao XY, Guo TK. RAPTOR promotes colorectal cancer proliferation by inducing mTORC1 and upregulating ribosome assembly factor URB1. *Cancer Med* 2020; **9**: 1529-1543 [PMID: 31886628 DOI: 10.1002/cam4.2810]

34 **Rahl PB**, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, Sharp PA, Young RA. c-Myc regulates transcriptional pause release. *Cell* 2010; **141**: 432-445 [PMID: 20434984 DOI: 10.1016/j.cell.2010.03.030]

35 **Morales F**, Giordano A. Overview of CDK9 as a target in cancer research. *Cell Cycle* 2016; **15**: 519-527 [PMID: 26766294 DOI: 10.1080/15384101.2016.1138186]

36 **Li X**, He S, Ma B. Autophagy and autophagy-related proteins in cancer. *Mol Cancer* 2020; **19**: 12 [PMID: 31969156 DOI: 10.1186/s12943-020-1138-4]

37 **Borden KLB**. CDK9 and mTOR: trading places. *Blood* 2019; **133**: 1167-1168 [PMID: 30872269 DOI: 10.1182/blood-2019-01-895086]

38 **Liao M**, Wang C, Yang B, Huang D, Zheng Y, Wang S, Wang X, Zhang J, Tang C, Xu Z, He Y, Huang R, Zhang F, Wang Z, Wang N. Autophagy Blockade by Ai Du Qing Formula Promotes Chemosensitivity of Breast Cancer Stem Cells Via GRP78/β-Catenin/*ABCG2* Axis. *Front Pharmacol* 2021; **12**: 659297 [PMID: 34149413 DOI: 10.3389/fphar.2021.659297]

39 **Wang N**, Yang B, Muhetaer G, Wang S, Zheng Y, Lu J, Li M, Zhang F, Situ H, Lin Y, Wang Z. XIAOPI formula promotes breast cancer chemosensitivity *via* inhibiting CXCL1/HMGB1-mediated autophagy. *Biomed Pharmacother* 2019; **120**: 109519 [PMID: 31629951 DOI: 10.1016/j.biopha.2019.109519]

40 **Guo T**, Liu DF, Peng SH. CDK9 is up-regulated and associated with prognosis in patients with papillary thyroid carcinoma. *Medicine (Baltimore)* 2022; **101**: e28309 [PMID: 35119000 DOI: 10.1097/MD.0000000000028309]

41 **Ma H**, Seebacher NA, Hornicek FJ, Duan Z. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma. *EBioMedicine* 2019; **39**: 182-193 [PMID: 30579871 DOI: 10.1016/j.ebiom.2018.12.022]

42 **Zhong M**, Xiong Y, Ye Z, Zhao J, Zhong L, Liu Y, Zhu Y, Tian L, Qiu X, Hong X. Microbial Community Profiling Distinguishes Left-Sided and Right-Sided Colon Cancer. *Front Cell Infect Microbiol* 2020; **10**: 498502 [PMID: 33324571 DOI: 10.3389/fcimb.2020.498502]

43 **Gervaz P**, Usel M, Rapiti E, Chappuis P, Neyroud-Kaspar I, Bouchardy C. Right colon cancer: Left behind. *Eur J Surg Oncol* 2016; **42**: 1343-1349 [PMID: 27178778 DOI: 10.1016/j.ejso.2016.04.002]

**Footnotes**

**Institutional review board statement:** The present study was approved by the Ethics Committee of Tianjin Medical University Cancer Institute and Hospital (Tianjin, China) (Approval No. Ek2019085). All methods were performed in accordance with relevant guidelines and regulations.

**Clinical trial registration statement:** Our study is purely observational in nature and does not involve any intervention. As such, it falls under the category of observational research rather than interventional research. Consequently, there was no clinical trial registration undertaken for this study.

**Informed consent statement:** Written informed consent for publication was obtained from all participants.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** The data that support the findings of this study are openly available in The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/repository?facetTab = cases&filters =%7B%22op%22%3A%22and%22%2C%22content%22%3A%5B%7B%22op%22%3A%22in%22%2C%22content%22%3A%7B%22field%22%3A%22cases.project.project\_id%22%2C%22value%22%3A%5B%22TCGA-COAD%22%2C%22TCGA-READ%22%5D%7D%7D%5D%7D). Data from clinical samples were not uploaded to the database.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 12, 2023

**First decision:** October 28, 2023

**Article in press:** January 5, 2024

**Specialty type:** Oncology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Dambrauskas Z, Lithuania; Eid N, Malaysia **S-Editor:** Li L **L-Editor:** A **P-Editor:** Zhang XD

**Figure Legends**



**Figure 1 Expression of cyclin-dependent kinase 9 in colorectal cancer tissues.** Expression of cyclin-dependent kinase 9 (CDK9) was extracted from The Cancer Genome Atlas. CDK9was significantly increased in colorectal cancer tissues compared to paired paracarcinoma tissues. CDK9: Cyclin-dependent kinase 9.




**Figure 2 Transmission electron microscopy.** Tissues with a high level of cyclin-dependent kinase 9 (CDK9) had significantly more autophagy than tissues with a low level of CDK9. Red arrows indicate the autophagosomes. CDK9-H: High level of cyclin-dependent kinase 9 expression; CDK9-L: Low level of cyclin-dependent kinase 9 expression; N: Paracarcinoma tissue; T: Tumor tissue.

图表, 图示


中度可信度描述已自动生成



**Figure 3 Kaplan–Meier curves of colorectal cancer patients.** A: Kaplan-Meier curves of overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in colorectal cancer patients with high and low expression levels of cyclin-dependent kinase 9 (CDK9); B: Kaplan-Meier curves of OS, DSS, and PFI of colon cancer patients with high and low expression levels of *BECN1*; C: Kaplan-Meier curves of OS, DSS, and PFI of rectum cancer patients with high and low expression levels of *BECN1*; D: Kaplan-Meier curves of DSS and PFI of colon cancer patients with high and low expression levels of *ABCG2*. HR: Hazard ratio.




**Figure 4 Level of autophagy in left and right colon cancer tissues.** A: Autophagosomes (black arrows) in left and right colon cancer and adjacent tissues observed under electron microscopy; B: Expression levels of autophagic vesicles in left and right colon cancer primary cells.





**Figure 5 Expression of *BECN1* (a key autophagy molecule) and *ABCG2* (a drug resistance factor) in left and right colon cancer tissue.** A: Expression of *BECN1* in left and right colon cancer tissues and paracarcinoma tissue; B: Expression of *ABCG2* in left and right colon cancer tissues and paracarcinoma tissue.





**Figure 6 Receiver operating characteristic curves of colorectal cancer patients.** A: Receiver operating characteristic (ROC) curves showed the accuracy of predicting the prognosis of rectal cancer (left figure) and colon cancer (right figure) by cyclin-dependent kinase 9 (CDK9)expression level; B: ROC curves showed the accuracy of the expression levels of *BECN1* in predicting the prognosis of rectal cancer; C: ROC curves showed the accuracy of predicting the prognosis in colon cancer (left figure) and rectal cancer (right figure) by the expression levels of *ABCG2*. CDK9: Cyclin-dependent kinase 9; AUC: Area under the curve; FPR: False positive rate; TPR: True positive rate.

**Table 1 Basic information of patients expressing cyclin-dependent kinase 9*, n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **Category** | **Low expression of CDK9, *n* = 322** | **High expression of CDK9, *n* = 322** | ***P* value** |
| T stage | T1 | 10 (1.6) | 10 (1.6) | 0.014 |
| T2 | 61 (9.5) | 50 (7.8) |  |
| T3 | 225 (35.1) | 211 (32.9) |  |
| T4 | 24 (3.7) | 50 (7.8) |  |
| N stage | N0 | 192 (30.0) | 176 (27.5) | 0.108 |
| N1 | 78 (12.2) | 75 (11.7) |  |
| N2 | 49 (7.7) | 70 (10.9) |  |
| M stage | M0 | 236 (41.8) | 239 (42.4) | 0.368 |
| M1 | 39 (6.9) | 50 (8.9) |  |
| Primary therapy outcome | PD | 13 (4.2) | 20 (6.4) | 0.185 |
| SD | 1 (0.3) | 4 (1.3) |  |
| PR | 10 (3.2) | 6 (1.9) |  |
| CR | 138 (44.2) | 120 (38.5) |  |
| Sex | Female | 143 (22.2) | 158 (24.5) | 0.269 |
| Male | 179 (27.8) | 164 (25.5) |  |
| CEA level | ≤ 5 | 135 (32.5) | 126 (30.4) | 0.944 |
| > 5 | 81 (19.5) | 73 (17.6) |  |
| Perineural invasion | No | 82 (34.9) | 93 (39.6) | 0.621 |
| Yes | 31 (13.2) | 29 (12.3) |  |
| Lymphatic invasion | No | 193 (33.2) | 157 (27) | 0.008 |
| Yes | 101 (17.4) | 131 (22.5) |  |
| History of colon polyps | No | 192 (34.6) | 185 (33.3) | 1.000 |
| Yes | 91 (16.4) | 87 (15.7) |  |
| Neoplasm type | Colon adenocarcinoma | 235 (36.5) | 243 (37.7) | 0.528 |
| Rectum adenocarcinoma | 87 (13.5) | 79 (12.3) |  |
| Age in yr, median (IQR) |  | 68.5 (60.0, 76.8) | 67.0 (57.0, 75.0) | 0.104 |

CDK9: Cyclin-dependent kinase 9; CEA: Carcinoembryonic antigen; PD: Progressive disease; PR: Partial response; SD: Stable disease; CR: Complete response; IQR: Interquartile range.

**Table 2 Basic information of patients expressing *ABCG2, n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **Category** | **Low expression of *ABCG2*, *n* = 322** | **High expression of *ABCG2*, *n* = 322** | ***P* value** |
| T stage | T1 | 15 (2.3) | 5 (0.8) | 0.114 |
| T2 | 54 (8.4) | 57 (8.9) |  |
| T3 | 219 (34.2) | 217 (33.9) |  |
| T4 | 33 (5.1) | 41 (6.4) |  |
| N stage | N0 | 209 (32.7) | 159 (24.8) | < 0.001 |
| N1 | 76 (11.9) | 77 (12.0) |  |
| N2 | 36 (5.6) | 83 (13.0) |  |
| M stage | M0 | 239 (42.4) | 236 (41.8) | 0.111 |
| M1 | 36 (6.4) | 53 (9.4) |  |
| Primary therapy outcome | PD | 12 (3.8) | 21 (6.7) | 0.305 |
| SD | 2 (0.6) | 3 (1.0) |  |
| PR | 10 (3.2) | 6 (1.9) |  |
| CR | 129 (41.3) | 129 (41.3) |  |
| Sex | Female | 143 (22.2) | 158 (24.5) | 0.269 |
| Male | 179 (27.8) | 164 (25.5) |  |
| CEA level | ≤ 5 | 127 (30.6) | 134 (32.3) | 0.986 |
| > 5 | 74 (17.8) | 80 (19.3) |  |
| Perineural invasion | No | 90 (38.3) | 85 (36.2) | 0.351 |
| Yes | 26 (11.1) | 34 (14.5) |  |
| Lymphatic invasion | No | 192 (33.0) | 158 (27.1) | 0.007 |
| Yes | 100 (17.2) | 132 (22.7) |  |
| History of colon polyps | No | 182 (32.8) | 195 (35.1) | 0.510 |
| Yes | 92 (16.6) | 86 (15.5) |  |
| Neoplasm type | Colon adenocarcinoma | 244 (37.9) | 234 (36.3) | 0.417 |
| Rectum adenocarcinoma | 78 (12.1) | 88 (13.7) |  |
| Age in yr, median (IQR) |  | 68.0 (59.0, 75.8) | 68.0 (57.3, 76.0) | 0.423 |

CDK9: Cyclin-dependent kinase 9; CEA: Carcinoembryonic antigen; PD: Progressive disease; PR: Partial response; SD: Stable disease; CR: Complete response; IQR: Interquartile range.

**Table 3 Basic information of patients expressing *BECN1, n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **Category** | **Low expression of *BECN1*, *n* = 322** | **High expression of *BECN1*, *n* = 322** | ***P* value** |
| T stage | T1 | 11 (1.7) | 9 (1.4) | 0.599 |
| T2 | 58 (9.0) | 53 (8.3) |  |
| T3 | 210 (32.8) | 226 (35.3) |  |
| T4 | 41 (6.4) | 33 (5.1) |  |
| N stage | N0 | 179 (28.0) | 189 (29.5) | 0.523 |
| N1 | 76 (11.9) | 77 (12.0) |  |
| N2 | 65 (10.2) | 54 (8.4) |  |
| M stage | M0 | 246 (43.6) | 229 (40.6) | 0.496 |
| M1 | 42 (7.4) | 47 (8.3) |  |
| Primary therapy outcome | PD | 16 (5.1) | 17 (5.4) | 0.775 |
| SD | 2 (0.6) | 3 (1.0) |  |
| PR | 10 (3.2) | 6 (1.9) |  |
| CR | 128 (41) | 130 (41.7) |  |
| Sex | Female | 149 (23.1) | 152 (23.6) | 0.874 |
| Male | 173 (26.9) | 170 (26.4) |  |
| CEA level | ≤ 5 | 126 (30.4) | 135 (32.5) | 0.477 |
| > 5 | 68 (16.4) | 86 (20.7) |  |
| Perineural invasion | No | 58 (24.7) | 117 (49.8) | 0.310 |
| Yes | 15 (6.4) | 45 (19.1) |  |
| Lymphatic invasion | No | 160 (27.5) | 190 (32.6) | 0.014 |
| Yes | 131 (22.5) | 101 (17.4) |  |
| History of colon polyps | No | 177 (31.9) | 200 (36) | < 0.001 |
| Yes | 113 (20.4) | 65 (11.7) |  |
| Neoplasm type | Colon adenocarcinoma | 234 (36.3) | 244 (37.9) | 0.417 |
| Rectum adenocarcinoma | 88 (13.7) | 78 (12.1) |  |
| Age in yr, median (IQR) |  | 69.0 (62.0, 77.0) | 65.5 (55.3, 75.0) | < 0.001 |

CDK9: Cyclin-dependent kinase 9; CEA: Carcinoembryonic antigen; PD: Progressive disease; PR: Partial response; SD: Stable disease; CR: Complete response; IQR: Interquartile range.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** office@baishideng.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2024 Baishideng Publishing Group Inc. All rights reserved.**